Results 161 to 170 of about 7,128 (244)

Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?

BJU International, EarlyView.
Objective To investigate the role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) treated with immune‐checkpoint inhibitors (ICIs). Methods A narrative review was carried out using PubMed and searching for English articles published from January 2015 to May 2025.
Rocco Simone Flammia, Riccardo Campi, Eugenio Bologna, Riccardo Bertolo, Costantino Leonardo, Fabio Calabrò, Daniele Amparore, Giuseppe Simone, on behalf of the Young Academic Urologists (YAU) Renal Cancer Working Group   +8 more
wiley   +1 more source

POS0479 Steroid-sparing effect of Janus kinase inhibitors compared to TNF inhibitors in rheumatoid arthritis: preliminary analysis from a single-center Italian cohort

Gilberto Cincinelli, V. Gerli, D. Pireddu, Giorgia Trignani, Francesco Ursini, A. Varvaro, Ennio Giulio Favalli, Roberto Caporali   +7 more
openalex   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

Tofacitinib: a janus kinase inhibitor for rheumatoid arthritis [PDF]

, 2017
Steve Chaplin
openalex   +1 more source

Efficacy of Upadacitinib in a Middle‐Aged Man With Netherton Syndrome Refractory to Dupilumab: A Case Report

The Journal of Dermatology, EarlyView.
Bo‐Jie Yu, Pei‐Ling Li, Bing‐Sian Lin, Shou‐En Wu, Chih‐Tsung Hung   +4 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

OP0032 Malignancies and serious infections in randomised controlled trials of janus kinase inhibitors in patients with rheumatoid arthritis: a systematic review and meta-analysis [PDF]

, 2018
María A. López-Olivo, Jean Tayar, Natalia Zamora, Gregory Pratt, María E. Suarez‐Almazor   +4 more
openalex   +1 more source

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence

British Journal of Pharmacology, EarlyView.
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska, Marta Baranowska‐Kuczko, Hanna Kozłowska   +2 more
wiley   +1 more source

Development of a Formulation and In Vitro Evaluation of a Pulmonary Drug Delivery System for a Novel Janus Kinase (JAK) Inhibitor, CPL409116 [PDF]

Aleksandra Rzewińska, Jakub Szlęk, Damian Dąbrowski, Ewelina Juszczyk, Katarzyna Mróz, Heikki Räikkönen, Mia Sivén, Maciej Wieczorek, Przemysław Dorożyński   +8 more
openalex   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source